Brief: CSPC Pharmaceutical Says Octreotide Long-Acting Injection Obtains FDA Clinical Trial Approval In U.S
18/06/2026 10:41
BRIEF-CSPC Pharmaceutical Says Octreotide Long-Acting Injection Obtains FDA Clinical Trial Approval In U.S June 18 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
OCTREOTIDE LONG-ACTING INJECTION OBTAINS FDA CLINICAL TRIAL APPROVAL IN U.S.
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC Pharmaceutical
See all newsBrief: CSPC Pharmaceutical Says NMPA Accepts Second Marketing Authorisation Application For Efmedaglutide Alfa Injection
Brief: CSPC Pharmaceutical Says NMPA Accepts Marketing Authorisation Application For Secukinumab Injection
Brief: CSPC Pharmaceutical Says Octreotide Long-Acting Injection Obtains FDA Clinical Trial Approval In U.S
Brief: CSPC Pharmaceutical NMPA Accepts Marketing Authorisation Application For Valsartan, Levamlodipine Maleate Tablets
Brief: CSPC Pharmaceutical Says Paclitaxel For Injection (Albumin-Bound) (Ii) Patented In China, US, And Europe